IPCALAB IPCA Laboratories Q4 FY26 results (Jan–Mar 2026) and concall
Ipca Labs reported a strong Q4 and FY26, driven by robust domestic formulation and US business growth, coupled with significant EBITDA margin expansion. While consolidated revenue and profitability showed healthy improvement, the institutional business faced headwinds, and Unichem's margins declined. Management provided optimistic guidance for FY27, anticipating continued growth and margin improvement despite rising raw material and freight costs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 6.3%, net profit up 379.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 +9% | 2,392 +7% | 2,388 +6% |
| EBITDA | 441 | 463 | 429 | 416 | 545 +24% | 533 +15% | 484 +13% |
| Net profit | 246 | 276 | 64 | 233 | 281 +14% | 364 +32% | 307 +380% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
